ORIC
NASDAQOric Pharmaceuticals Inc.
Price$12.35-0.06 (-0.48%)
01:30 PM07:45 PM
News · 26 weeks41+125%
2026-04-192026-10-11
Mix2190d
- Other7(33%)
- SEC Filings7(33%)
- Insider5(24%)
- Analyst2(10%)
Latest news
25 items- PRORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the world’s largest funders of cancer research, to adv
- ANALYSTLeerink Partners initiated coverage on ORIC Pharmaceuticals with a new price targetLeerink Partners initiated coverage of ORIC Pharmaceuticals with a rating of Outperform and set a new price target of $26.00
- INSIDERDirector Heyman Richard A. exercised 3,500 shares at a strike of $1.60 and sold $86,524 worth of shares (6,700 units at $12.91) as part of a pre-agreed trading plan (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the "Grant Date"), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The
- SECSEC Form 144 filed by Oric Pharmaceuticals Inc.144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- SECSEC Form 144 filed by Oric Pharmaceuticals Inc.144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- INSIDERChief Financial Officer Piscitelli Dominic exercised 13,400 shares at a strike of $4.36 and sold $181,258 worth of shares (13,400 units at $13.53) as part of a pre-agreed trading plan (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- INSIDERChief Financial Officer Piscitelli Dominic exercised 600 shares at a strike of $4.36 and sold $8,102 worth of shares (600 units at $13.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- ANALYSTBTIG Research initiated coverage on ORIC Pharmaceuticals with a new price targetBTIG Research initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $26.00
- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the "Grant Date"), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The s
- PRORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference – Participating in a fireside chat on Wednesday, September 9, 2026, at 2:15 p.m. ET. Management will also be participating in one-on-one meetings.2026 Cantor Global Healthcare Conference – Participating in a fireside chat on Thursday, September 10, 2026, at 1:35 p.m. ET. Management will
- INSIDERChief Financial Officer Piscitelli Dominic exercised 77,000 shares at a strike of $4.89 and sold $1,053,814 worth of shares (77,000 units at $13.69) as part of a pre-agreed trading plan (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- SECSEC Form 144 filed by Oric Pharmaceuticals Inc.144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the "Grant Date"), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees who began their employment with ORIC in July 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stoc
- SECSEC Form 10-Q filed by Oric Pharmaceuticals Inc.10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECOric Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- PRORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational UpdatesInitiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncolo
- SECSEC Form S-8 filed by Oric Pharmaceuticals Inc.S-8 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECSEC Form 8-K filed by Oric Pharmaceuticals Inc.8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- INSIDERDirector Heyman Richard A. exercised 3,500 shares at a strike of $1.60 and sold $157,462 worth of shares (13,100 units at $12.02) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 38,300 units (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- PRORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three po
- PRORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with BayerInitiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and announced a clinical trial collaborat
- INSIDERDirector Heyman Richard A. sold $3,600 worth of shares (300 units at $12.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- SECSEC Form 144 filed by Oric Pharmaceuticals Inc.144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- SECSEC Form 144 filed by Oric Pharmaceuticals Inc.144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
ORIC FAQ
7 questionsWhat does Oric Pharmaceuticals Inc. do?
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer...Where does ORIC stock trade?
Oric Pharmaceuticals Inc. (ORIC) is listed on NASDAQ.What sector and industry is ORIC in?
Oric Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Oric Pharmaceuticals Inc. go public?
Oric Pharmaceuticals Inc. (ORIC) completed its IPO in 2020.What are analysts saying about ORIC?
Oric Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $2600.00 price target on 2026-10-05. Recent price targets range from $1400.00 to $2600.00.What companies are similar to ORIC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ORIC side-by-side with any of them on Quantisnow.How can I track ORIC on Quantisnow?
Quantisnow aggregates Oric Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORIC to receive live email and push alerts on every new disclosure.